AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02046733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
Study NCT02046733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
Study NCT03606629 — intervention group
Intervention type: DEVICE
Intervention: Endoprosthesis implantation
Description: Endoprosthesis implantation by Percutaneous Angioplasty
Study NCT02487290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aneufix ACP-T5
Description: The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
Study NCT02206685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
Study NCT02206685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
Study NCT04442672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute compartment syndrome model of health volunteer
Description: the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
Study NCT04442672 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: surrounding the cuff but not inflate it.
Study NCT00072475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
Study NCT02649114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy
Study NCT02649114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Study NCT03743519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: 30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
Study NCT03743519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in taste and colour to the Cherry juice, but with no anthocyanin content
Study NCT00597974 — intervention group
Intervention type: PROCEDURE
Intervention: Angioplasty
Description: (non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectnib
Description: Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
Study NCT03456076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
Study NCT00597974 — intervention group
Intervention type: DEVICE
Intervention: Stent
Description: (non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
Study NCT00597974 — intervention group
Intervention type: OTHER
Intervention: Neurological and neuropsychological evaluations
Description: Clinical examinations consisting of a neurological and neuropsychological evaluation
Study NCT04415151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
Study NCT04415151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be administered.
Study NCT02167347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
Study NCT06437457 — intervention group
Intervention type: RADIATION
Intervention: ceus
Description: MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
Study NCT00597974 — intervention group
Intervention type: PROCEDURE
Intervention: Angiography
Description: (non-experimental) Coronary angiography
Study NCT00731016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zoledronic acid, pravastatin
Description: Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid
Study NCT05235243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring
Description: An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
Study NCT05235243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online therapeutic intervention for maladaptive daydreaming based on mindfulness
Description: An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
Study NCT00886912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia
Description: training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
Study NCT00886912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normoxia
Description: training under normoxic conditions
Study NCT00662688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daltéparine
Study NCT00662688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy at the investigator's discretion
Study NCT00662688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy at the investigator's discretion
Study NCT04072562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.
Study NCT04072562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7594
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.
Study NCT01200862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug company code: BGS649
Study NCT01200862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00619138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual cognitive-behavioural therapy
Description: 1 session per week for 12 weeks
Study NCT00619138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stepped care model
Description: three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
Study NCT01141764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Scan
Description: The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days.
Study NCT01141764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
Study NCT01141764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Testing
Description: On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on.
Study NCT02695771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Cancer chemotherapeutic agent
Study NCT02695771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Cancer chemotherapeutic agent
Study NCT01500135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
Study NCT01500135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel® Original
Description: Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
Study NCT04559932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracheostomy Training Course
Description: A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
Study NCT02018666 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAVA endotracheal tube
Study NCT02018666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA endotracheal tube
Study NCT03997968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with gemcitabine
Description: Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
Study NCT03997968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with capecitabine
Description: Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
Study NCT03997968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT-0851 in combination with rituximab and bendamustine
Description: Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
Study NCT02514603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study NCT03775031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
Study NCT04187703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: 5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
Study NCT04187703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
Study NCT03985046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Chemotherapy
Description: Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
Study NCT03775031 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional Laser and Chemical Peel
Description: Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
Study NCT02043301 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the abdomen
Study NCT02725060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
Study NCT02925143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning course in neuromuscular monitoring
Description: An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
Study NCT02725060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoproterenol
Description: Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
Study NCT04018729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zephyr Endobronchial Valve
Description: Endoscopic lung volume reduction therapy.
Study NCT02725060 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 25 micro-Ci of radiation
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
Study NCT02725060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture study with blood samples
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
Study NCT02725060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hour heart rhythm and blood pressure monitoring
Description: Blood pressure, heart rate and ECG monitoring for 24 hours
Study NCT02725060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Axonal Sudomotor Reflex Testing
Description: The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
Study NCT02725060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic function tests
Description: The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
Study NCT02725060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebreathing test
Description: Cardiac output will be measured using the rebreathing technique (Innocor)
Study NCT02725060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of splanchnic capacitance
Description: Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
Study NCT02725060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microneurography
Description: microneurography will be measured in the peroneal nerve to assess sympathetic activity.
Study NCT02171897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Study NCT02171897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Study NCT01406249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP
Description: Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle.
Study NCT01406249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP
Description: Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Study NCT04559750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered behavior therapy (I-BT)
Description: 10 weeks of I-BT